PTOISB/08x (08-03)
Approved for use through 07/31/2006 (008-068)
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
ond to a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction Act of 1995, no persons are required to resp

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number			
	Filing Date			
	First Named Inventor Udo VAN STEVENDAAL			
	Art Unit			
	Examiner Name			
	Attorney Docket Number	er	PHDE030418US	

				U.S.	PATENTS		Remove	
Examiner Cite Patent Number		Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document				
	1	3965358		1976-06-22	Macovski	all		
	2	4714997		1987-12-22	Crawford, et al.	all		
	3	6430252		2002-08-06	Reinwand, et al.	all		
	4	6600801	B2	2003-07-29	Raupach	all		
If you wis	h to ac	dd additional U.S. Paten	t citatio	n information pl	ease click the Add button.		Add	
			U.S.P	ATENT APPLI	CATION PUBLICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant Releva		Columns, nt Passag Appear	Lines where ges or Relevant
	1	20020018540	A1	2002-02-14	Stierstorfer	all		
	2	20030004405	A1	2003-01-02	Townsend, et al.	all		

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		
Filing Date		
First Named Inventor Udo		VAN STEVENDAAL
Art Unit		
Examiner Name		
Attorney Docket Numb	or	PHDE030418US

Date Considered

	3	20030031299	A1	2003-0	2-13	Ohishi		all		
If you wis	If you wish to add additional U.S. Published Application citation information please click the Add button. Add									
	FOREIGN PATENT DOCUMENTS Remove									
Examiner Initial*	Cite No	Foreign Document Number ³			Kind Code ⁴		Applicant of cited		Pages,Columns,Lir where Relevant Passages or Relevant Figures Appear	T5
	1								all	
If you wis	If you wish to add additional Foreign Patent Document citation information please click the Add button Add									
NON-PATENT LITERATURE DOCUMENTS Remove										
Examiner lititals* Cite include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposibum, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.								T5		
	VAN DE CASTEELE, E., et al.: A bimodal energy model for correcting beam hardening ariefacts in X-ray tomography; 2003; IEEE Proc. of the 25th Northeast Bioengineering Conf.; pp. 57-58.								w:	
If you wish to add additional non-patent literature document citation information please click the Add button Add										
	EXAMINED CIQUATION									

1 Sex Kno Codes of USPTO Potent Documents at sprey USPTO_CODY or MEPS 901.6. 2 failer office that assed the document, by the involvator code (WPO Standard 57.3). 25 or departers parted recovered, he evaluated not they were of the region of the Emperor note precede the serial recover of the parted or the parte

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Signature

Application Number Filing Date Filing Date

CERTIFICATION STATEMENT

Please see 3	7 CFR 1	1.97 and	1.98 to make 1	the appropriate selection(s):	
--------------	---------	----------	----------------	-------------------------------	--

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(eVI).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no tem of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(eV).

- See attached certification statement.
- Fee set forth in 37 CFR 1,17 (p) has been submitted herewith.
- 7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Thomas M. Lundin/	Date (YYYY-MM-DD)	2006-06-13
Name/Print	Thomas M. Lundin	Registration Number	48979

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenant Afford, U.S. Department of Commence, P. 0. Bast 1436, Alexandria, V.S. 2311.1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2.2311.4450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.